How Will You Feel During HIV Treatment?

Current combinations of HIV medications have changed the nature of HIV from a terminal illness to one that allows you to live out a nearly normal life. Yet the powerful antiretroviral drugs that help control the virus are known to cause side effects once you start treatment.

Not everyone is affected the same way by the same drugs. You might find the side effects are mild and go away in a few weeks, once your body adapts to the new chemicals. Nausea, diarrhea, and headaches tend to lessen after a month or so.

Read more: How Will You Feel During HIV Treatment?

Source: healthguides

Cholesterol: Types, Treatments, and Lifestyle Changes

Source: Healthline Networks

Precision Medicine in Oncology

The White House Proposes Increased Funding For a National Precision Medicine Initiative

In his 2015 State of the Union address, President Obama stated his intention to fund a national Precision Medicine Initiative (PMI), defined by the NIH as an emerging approach for disease prevention and treatment that takes into account individual variations in genes, environment, and lifestyle.

The White House said that it will ask Congress for $215 million to fund the assembly of databases. Through the data, from over one million patients, scientists and researchers will be able to individualize care and generate the requisite scientific evidence to move the concept of precision medicine into clinical practice.

The initiative, in the near-term, focuses on cancer, with other disease areas included over the longer term. Of the $215 million, the White House proposed $70 million in increased funding for the NCI to advance the field of precision oncology.

Basically the initiative funds efforts to integrate and apply the explosion of molecular data on humans, particularly data associated with individual patients, and taps into opportunities to use it to improve health outcomes. The “time is right” for the initiative, NIH says, because of the sequencing of the human genome, improved technologies for biomedical analysis, and new tools for using large datasets.

Read more: Precision Medicine in Oncology

MATCH clinical trials analyze tumors for abnormalities using a targeted sequencing

assay that includes 143 genes selected using the Oncomine Knowledgebase.

Source: Deposit Photos/alexraths

Latest progress in diagnosis and treatment of Sarcomas

What are sarcomas?

Sarcomas are rare tumours of connective tissue, and as a result they can affect any part of the body. These are tumours of fat, nerves, bone, tendons, muscle and skin. They account for about 1% of all adult cancers and approximately 15% of pediatric tumours. In addition to the wide distribution of potential primary sites and the rarity, these are also very heterogeneous tumours with over 80 different histological subtypes.

These 3 factors make sarcomas extremely challenging to treat. Consequently, it is very important that sarcoma patients are managed by an experienced multi-disciplinary team, including surgeons, pathologists, radiologists, oncologists, specialist nurses, physiotherapists and pharmacists.

Diagnosis

In order to make the diagnosis a biopsy is required to confirm the presence of a sarcoma and the specific subtype. Because these tumours are so rare and heterogeneous it is essential that an experienced pathologist reviews the biopsy sample. Initial diagnostic radiology tests can include a CT and MRI scan depending on the location and type of sarcoma.

Treatment

The mainstay of treatment of localized sarcomas includes complete surgical removal with or without radiation. It is important that an experienced surgeon performs surgery as improperly performed surgery can have an impact on outcome.

Read more: Latest progress in diagnosis and treatment of Sarcomas

A sarcoma is a cancer. Sarcoma - malignant tumors made of cancellous bone, cartilage,

fat, muscle, vascular, and tissues.

Source: Designua/Shutterstock

Colorectal cancer

Colorectal cancer had a low incidence several decades ago. However, it has become a predominant cancer and now accounts for approximately 10% of cancer-related mortality in western countries. The ‘rise’ of colorectal cancer in developed countries can be attributed to the increasingly ageing population, unfavourable modern dietary habits and an increase in risk factors, such as smoking, low physical exercise and obesity. New treatments for primary and metastatic colorectal cancer have emerged, providing additional options for patients; these treatments include laparoscopic surgery for primary disease, more-aggressive resection of metastatic disease (such as liver and pulmonary metastases), radiotherapy for rectal cancer, and neoadjuvant and palliative chemotherapies. However, these new treatment options have had limited impact on cure rates and long-term survival. For these reasons, and the recognition that colorectal cancer is long preceded by a polypoid precursor, screening programmes have gained momentum. This Primer provides an overview of the current state of the art of knowledge on the epidemiology and mechanisms of colorectal cancer, as well as on diagnosis and treatment.

Introduction

We live in an era with improved worldwide average living standards and increased access to adequate health care that has considerably improved the diagnosis and treatment of diseases. These measures have had an effect on the average life expectancy in most regions of the world. However, although death rates from communicable diseases have improved globally as a result of these medical improvements, cancer-related mortality has increased by almost 40% over the past 40 years. A further 60% increase is expected in the next 15 years, with 13 million people estimated to die of cancer in 2030. The main causes of cancer-related mortality have also changed, attributable to alterations in disease incidence, the introduction of screening programmes and therapeutic improvements. Colorectal cancer was rather rare in 1950, but has become a predominant cancer in western countries, now accounting for approximately 10% of cancer-related mortality. Reasons explaining this increased incidence include an ageing population and the preponderance of poor dietary habits, smoking, low physical activity and obesity in western countries. The change in incidence is not only apparent in the rates of sporadic disease but also in some familial cancer syndromes. Indeed, given that the rates of Helicobacter pyloriinfection (a causative factor of gastric cancer) have fallen dramatically, colorectal cancer is now the predominant presentation of Lynch syndrome (a hereditary non-polyposis type of colorectal cancer), whereas carriers of this syndrome used to be predominantly affected by gastric cancer.

Read more: Colorectal cancer

Source: krmc

Gastritis: Facts, Causes, Diagnosis and Treatment

Gastritis is the inflammation of the stomach lining, which can have a multitude of causes.

The condition can be an acute (sudden onset, short-term) or chronic (persistent, long-term) issue that increases the risk of other conditions such as stomach ulcers, bleeding or cancer.

Facts about gastritis.

• Gastritis can increase the risk of other gastrointestinal conditions such as stomach ulcers and cancer
• People with gastritis typically report that their abdominal pain is located in the upper center of the abdomen
• Gastritis can also cause pain in the upper left portion of the stomach radiating to the back
• Pain caused by gastritis is often described as sharp, stabbing or burning
• Treatment of gastritis depends on the factors that caused the illness along with whether the disease is acute or chronic.

Causes of gastritis

Gastritis occurs when the protective mucus lining of the stomach is weakened. When this happens, the digestive juices in the stomach can damage and inflame the walls of the stomach.

Read more: Gastritis: Facts, Causes, Diagnosis and Treatment

Gastritis occurs when the mucus lining of the stomach is weakened, enabling the digestive juices
to damage the stomach wall.

Source: steptohealth